Drugs / NADECNEMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03645746 | Aug 2018 → Sep 2019 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03956550 | May 2019 → May 2020 | osteoarthritis, knee | Regeneron Pharmaceuticals | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NADECNEMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650510 ↗ |
| Known as | REGN5069 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03956550 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650510 ↗ |
| Route | Intravenous | “REGN5069 will be administered by IV infusion or SC injection” NCT03645746 ↗ |
| Route | Subcutaneous | “REGN5069 will be administered by IV infusion or SC injection” NCT03645746 ↗ |